Bioheart

bioheart is committed to maintaining a leading position within the cardiovascular sector of the cell technology industry delivering cell therapies, intelligent devices and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. the company works to prevent the worsening of any condition employing devices that monitor and diagnose. bioheart's expertise is regenerating damaged tissue, if possible, and improving a patient's quality of life in addition to reducing health care costs and hospitalizations. specific to biotechnology, the company is focused on the discovery, development and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease, subject to regulatory approval. myocell, the company's principal therapy, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart wi